

Sven-Erik Strand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/163986/publications.pdf>

Version: 2024-02-01

52
papers

764
citations

516710

16
h-index

580821

25
g-index

54
all docs

54
docs citations

54
times ranked

1000
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Magnetomotive ultrasound, PET/CT, and MR imaging of ⁶⁸ Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo. <i>Scientific Reports</i> , 2017, 7, 4824.	3.3	62
2	Pharmacokinetic modeling. <i>Medical Physics</i> , 1993, 20, 515-527.	3.0	49
3	Distribution of iodine ¹²⁵ I-labelled $\hat{\pm}$ 1-microglobulin in rats after intravenous injection. <i>Translational Research</i> , 2001, 137, 165-175.	2.3	46
4	A Monte Carlo Program Converting Activity Distributions to Absorbed Dose Distributions in a Radionuclide Treatment Planning System. <i>Acta OncolÃ³gica</i> , 1996, 35, 367-372.	1.8	40
5	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. <i>Nature Communications</i> , 2018, 9, 1629.	12.8	37
6	Radioimmunotherapy Dosimetryâ€”A Review. <i>Acta OncolÃ³gica</i> , 1993, 32, 807-817.	1.8	31
7	The LundADose Method for Planar Image Activity Quantification and Absorbed-Dose Assessment in Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 92-97.	1.0	30
8	Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies. <i>Acta OncolÃ³gica</i> , 2011, 50, 973-980.	1.8	30
9	(⁶⁸ Ga)-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 4, 60-9.	1.0	28
10	Optimizing retention of multimodal imaging nanostructures in sentinel lymph nodes by nanoscale size tailoring. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e1089-e1095.	3.3	25
11	¹⁸⁸ Re-Z _{HER2:V2} , a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1842-1848.	5.0	23
12	Internalization of secreted antigenâ€”targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. <i>Science Translational Medicine</i> , 2016, 8, 367ra167.	12.4	23
13	Radioimmunotherapy for Prostate Cancerâ€”Current Status and Future Possibilities. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 165-179.	4.6	23
14	Protection of Kidney Function with Human Antioxidation Protein $\hat{\pm}$ 1-Microglobulin in a Mouse ¹⁷⁷ Lu-DOTATATE Radiation Therapy Model. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 1746-1759.	5.4	22
15	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 881-891.	7.0	21
16	Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a ¹¹¹ In-radiolabelled monoclonal antibody, 11B6. <i>EJNMMI Research</i> , 2014, 4, 51.	2.5	20
17	Preclinical efficacy of hK2 targeted [¹⁷⁷ Lu]hu11B6 for prostate cancer theranostics. <i>Theranostics</i> , 2019, 9, 2129-2142.	10.0	17
18	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted $\hat{\pm}$ -particle therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15172-15181.	7.1	16

#	ARTICLE	IF	CITATIONS
19	Quantitative \hat{I}^3 -H2AX immunofluorescence method for DNA double-strand break analysis in testis and liver after intravenous administration of $^{111}\text{InCl}_3$. <i>EJNMMI Research</i> , 2020, 10, 22.	2.5	15
20	Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with ^{90}Y or ^{177}Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 7104s-7108s.	7.0	13
21	Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with ^{177}Lu - and ^{90}Y -BR96 mAbs. <i>Medical Physics</i> , 2012, 39, 4434-4443.	3.0	13
22	Intratherapeutic Biokinetic Measurements, Dosimetry Parameter Estimates, and Monitoring of Treatment Efficacy Using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 444-449.	5.0	13
23	Simultaneous Preclinical Positron Emission Tomography-Magnetic Resonance Imaging Study of Lymphatic Drainage of Chelator-Free ^{64}Cu -Labeled Nanoparticles. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 213-220.	1.0	13
24	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. <i>Clinical Cancer Research</i> , 2021, 27, 2050-2060.	7.0	13
25	Human Anti-Oxidation Protein A1M – A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 30309-30320.	4.1	12
26	Biodistribution and pharmacokinetics of recombinant $\hat{I}^{\pm}1$ -microglobulin and its potential use in radioprotection of kidneys. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 333-47.	1.0	12
27	Parameters Influencing Volume and Activity Quantitation in Spect. <i>Acta Oncol³gica</i> , 1996, 35, 323-330.	1.8	11
28	^{177}Lu -PSMA-617 Therapy in Mice, with or without the Antioxidant $\hat{I}^{\pm}1$ -Microglobulin (A1M), Including Kidney Damage Assessment Using $^{99\text{m}}\text{Tc}$ -MAG3 Imaging. <i>Biomolecules</i> , 2021, 11, 263.	4.0	10
29	Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution. <i>Nuclear Medicine and Biology</i> , 2015, 42, 375-380.	0.6	9
30	Cancer Cell Radiobiological Studies Using In-House-Developed \hat{I}^{\pm} -Particle Irradiator. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 386-394.	1.0	9
31	Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ^{177}Lu Compared to Alpha Particles and Gamma Rays. <i>Anticancer Research</i> , 2016, 36, 103-9.	1.1	8
32	Influence of a reticuloendothelial-suppressing agent on liver tumor growth in the rat. <i>Journal of Surgical Oncology</i> , 1984, 26, 245-251.	1.7	7
33	Improving Radioimmunotargeting of Tumors: Variation in the Amount of L6 Mab Administered, Combined with an Immunoabsorption System (Ecia). <i>Acta Oncol³gica</i> , 1993, 32, 853-859.	1.8	7
34	Beta Camera Low Activity Tumor Imaging. <i>Acta Oncol³gica</i> , 1993, 32, 869-872.	1.8	6
35	The Combination of In vivo ^{124}I -PET and CT Small Animal Imaging for Evaluation of Thyroid Physiology and Dosimetry. <i>Diagnostics</i> , 2012, 2, 10-22.	2.6	6
36	Characterization of a double-sided silicon strip detector autoradiography system. <i>Medical Physics</i> , 2015, 42, 575-584.	3.0	6

#	ARTICLE	IF	CITATIONS
37	Development of a Hybrid Nanoprobe for Triple-Modality MR/SPECT/Optical Fluorescence Imaging. <i>Diagnostics</i> , 2014, 4, 13-26.	2.6	5
38	Using Rose's metal alloy as a pinhole collimator material in preclinical smallâ€œanimal imaging: A Monte Carlo evaluation. <i>Medical Physics</i> , 2015, 42, 1698-1709.	3.0	5
39	A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen. <i>Cancers</i> , 2021, 13, 3469.	3.7	5
40	Kidney Protection with the Radical Scavenger Î±1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy. <i>Antioxidants</i> , 2021, 10, 1271.	5.1	5
41	Hematological Toxicity in Mice after High Activity Injections of ¹⁷⁷ Lu-PSMA-617. <i>Pharmaceutics</i> , 2022, 14, 731.	4.5	4
42	Plasma exudation in the skin measured by external detection of conversion electrons. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 290-294.	2.1	3
43	Superparamagnetic iron oxide nanoparticles as a multimodal contrast agent for up to five imaging modalities. <i>Clinical and Translational Imaging</i> , 2015, 3, 247-249.	2.1	3
44	High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors. <i>Medical Physics</i> , 2016, 43, 6632-6643.	3.0	3
45	Size-dependent lymphatic uptake of nanoscale-tailored particles as tumor mass increases. <i>Future Science OA</i> , 2015, 1, FSO60.	1.9	2
46	Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1964-1970.	5.0	2
47	Multi-radionuclide digital autoradiography of the intra-aortic atherosclerotic plaques using a monoclonal antibody targeting oxidized low-density lipoprotein. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 172-80.	1.0	1
48	An attenuation method for reducing count rate losses in preclinical PET during intratherapeutic imaging. , 2016, , .		0
49	Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux. <i>Journal of Nuclear Medicine</i> , 2019, 60, 710-715.	5.0	0
50	An aggressive RhoC phenotype is associated with relapse after external beam radiation therapy of a prostate cancer xenograft model.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14748-e14748.	1.6	0
51	Preclinical evaluation of (¹¹¹ In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 311-23.	1.0	0
52	Humanization, Radiolabeling and Biodistribution Studies of an IgG1-Type Antibody Targeting Uncomplexed PSA for Theranostic Applications. <i>Pharmaceutics</i> , 2021, 14, 1251.	3.8	0